A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Inclusion Criteria: * Patient must be capable, willing, and able to provide written, informed consent. * Age ≥ 18-years-old and \<= 75-years-old. * Histologic confirmation of multiple myeloma by the enrolling institution * Symptomatic myeloma that has progressed/relapsed after 1 to 3 prior lines of therapy * Patients who have received \<=1 cycle of therapy after most recent progression/relapse are eligible to enroll on study * Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted * Bisphosphonates are permitted * Concurrent or prior treatment with corticosteroids for indications other than multiple myeloma is permitted * Prior treatment with radiotherapy is permitted * Patients with measurable disease who received up to one cycle of any therapy within 60 days with a washout period of 4 weeks from last dose (on a trial or outside a trial) are eligible * Maintenance single agent imid (ie. lenalidomide or pomalidomide) or monoclonal antibody (ie. daratumumab) do not require the 4-week washout period * More than 2 x 10\^6 autologous CD34+ cells/kg cryopreserved. The graft may not be CD34+ selected or otherwise manipulated to remove tumor or other cells. The graft can be collected at the transplanting institution or by a referring center. * Planning to receive autologous HCT per institutional standards as part of standard of care. Eligibility for autologous HCT should be based on i…